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Abstract
Cancer stem cells (CSCs) are a subpopulation of tumor cells with preferential tumor-initiating capacity and have
been purported to be resistant to chemotherapy. It has been shown that breast CSC are, on average, enriched in
patient tumors after combination neoadjuvant chemotherapy including docetaxel, doxorubicin, and cyclophospha-
mide (CPA). Here, we investigate the resistance of breast CSC to CPA alone in a xenograft model. CPA treatment
led to a 48% reduction in tumor volume during a 2-week period. Cells bearing the CD44+ CD24− phenotype were
reduced by 90% (2.5% to 0.24%) in CPA-treated tumors, whereas cells with aldehyde dehydrogenase activity were
reduced by 64% (4.7% to 1.7%). A subsequent functional analysis showed that CPA-treated tumors were impaired
in their ability to form tumors, indicating loss of functional tumor-initiating activity. These results are consistent
with a CSC phenotype that is sensitive to CPA and indicate that some patient CSC may not display the expected re-
sistance to therapy. Deciphering the mechanism for this difference may lead to therapies to counteract resistance.
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Introduction
Tumor resistance to chemotherapeutics is an important problem fac-
ing oncology, which ultimately leads to tumor progression and mor-
tality. The mechanisms of resistance may take many forms, including
multidrug transporter activity, altered signaling networks, enhanced
DNA repair, detoxification, and others. One proposed cause of resis-
tance is derived from the cancer stem cell (CSC) hypothesis [1].
The CSC hypothesis maintains that a small subset of cells in a
tumor are solely endowed with the capacity to propagate the tumor
and maintain its growth [2]. In parallel to normal stem cells, CSCs
are thought to have self-renewal activity and produce daughter cells
that differentiate to be incorporated into the growing tumor. Like-
wise, because normal stem cells often exhibit relative resistance to
a variety of therapeutic agents, it has been hypothesized that CSCs
also exhibit this phenomenon [1,2]. In support of this hypothesis,
the literature shows enrichment of CD44+ CD24− CSCs in breast
cancer patients undergoing neoadjuvant therapy [3].
In this work, we test the hypothesis that breast CSC are resistant
to cyclophosphamide (CPA). Our results show that CPA treatment of
xenografts derived from a breast cancer patient results in a reduction in
tumor volume and loss of cells containing CSC markers. These tumors
were impaired in their ability to form tumors in secondary nonobese
diabetic–severe combined immunodeficient (NOD/SCID) mice,
proving a functional loss of stem cell activity. Thus, we propose that
resistance to chemotherapeutics is not a global property of breast CSC
but is a continuum that is determined by individual characteristics.
Materials and Methods
Tumors and Mice
MC1 cells have been previously described and are derived from
metastatic breast tumor tissue [4]. They have been passaged as xeno-
grafts (<10 passages since derivation) and have been described as ER−,
PR−, and HER2− [5].
To produce tumors, NOD/SCID mice ( Jackson Laboratories, Bar
Harbor, ME) were injected with 106 cells (unless otherwise specified)
into themammary fat pad in a 1:1 mixture ofMatrigel (BDBiosciences,
San Jose, CA) and serum-free Dulbecco’s modified Eagle medium.
Single-cell suspensions were made by chopping tumor with a razor
blade followed by incubation at 37°C for 15 minutes in a collagenase/
hyaluronidase solution (Stem Cell Technologies, Vancouver, Canada)
in Medium 199 (Gibco, Carlsbad, CA). The suspension was then
triturated through a 16-gauge needle, and the reaction was stopped
by the addition of Hank’s balanced salt solution and 5% FBS and
Address all correspondence to: Steven P. Zielske, PhD, 4310 Med Sci I, Department of
Radiation Oncology, University of Michigan, Ann Arbor, MI 48109.
E-mail: szielske@med.umich.edu
1This work was supported by the Elsa U. Pardee Foundation (S.P.Z.) and a LUNGevity
Foundation–American Cancer Society fellowship (S.P.Z.).
Received 16 October 2009; Revised 16 October 2009; Accepted 20 November 2009
Copyright © 2010 Neoplasia Press, Inc. All rights reserved 1944-7124/10/$25.00
DOI 10.1593/tlo.09307
www.transonc.com
Trans la t iona l Onco logy Volume 3 Number 3 June 2010 pp. 149–152 149
then filtered through a 100-μm strainer. Cells were washed with
Hank’s balanced salt solution and 5% FBS and were filtered a second
time through a 100-μm strainer. Cells were frozen in 85% FBS and
15% DMSO.
Flow Cytometry
Flow cytometry for CD44+ CD24− lin− cells was done as described
[4]. All antibodies were from BD Pharmingen (San Jose, CA). Line-
age cocktail consisted of anti-CD3, CD10, CD16, CD140b, and
CD18. Only live, human cells were counted based on propidium io-
dide exclusion and lack of H2-kd expression, respectively.
Flow cytometry for aldehyde dehydrogenase (ALDH) activity was
done according to the instructions included in the ALDEFLUOR
Kit (Stem Cell Technologies). Positive activity was confirmed by in-
hibition with diethyl amino-benzaldehyde.
Immunofluorescence
ALDH immunofluorescence was performed on paraffin-embedded
tumor sections after antigen retrieval for 30 minutes in sodium citrate
during a 100°C water bath. Sections were blocked in TBS, 1% BSA,
and 10%normal goat serum for 2 hours andwere incubated at 4°C over-
night in 1:100 anti-ALDH antibody (no. 611195; BD Pharmingen).
Sections were then incubated in 1:1000 donkey antimouse Alexa Fluor
488 secondary antibody (no. A21202; Invitrogen, Carlsbad, CA) for
1 hour at room temperature. Sections were mounted with Prolong Gold
(Invitrogen) containing 4′-6-diamidino-2-phenylindole for staining
of nuclei.
Results
Decreased Tumor Volume in Response to CPA Treatment
We began by determining the effect of CPA, a standard part of
neoadjuvant therapy for breast cancer, on the growth rate and histo-
logical appearance of breast xenografts derived from a patient tumor
(MC1), which has been reported to reflect the morphologic and pheno-
typic characteristics of the original tumor [4].
MC1 xenografts were grown in the mammary fat pads of NOD/
SCID mice and allowed to reach 1200 to 2200 mm3 before initiation
of treatment. Mice were treated intraperitoneally with 100 mg/kg
CPA every other day for a total of four treatments. Tumors continued
to increase in size 2 days after the initiation of CPA treatment (Fig-
ure 1B). Subsequently, a progressive reduction in tumor volume
was noted through a 12-day period, ending with tumor harvesting
at 14 days. At the 12-day time point, a 48% reduction in tumor vol-
ume was observed. Tumors removed 2 weeks after the start of treat-
ment were assessed histologically by staining with hematoxylin/eosin
and were found to display gross breakdown of tumor tissue architec-
ture and indications of cell death throughout the tumor in all histo-
logical sections analyzed, in contrast to control tumors (Figure 1A).
These data show that MC1 tumors respond to CPA monotherapy,
which leads to a substantial disruption of tumor organization and
decreased tumor volume.
CPA Treatment Causes a Loss of Cells Bearing CSC
Phenotypic Markers
Breast CSCs were originally defined as being in a population that
are CD44+ CD24− lin− [4], whereas more recently, breast cancer cells
with ALDH1 activity were reported to be enriched for CSCs [5]. We
used flow cytometry to measure the proportion of cells displaying
these phenotypes in untreated or CPA-treated xenografts as an indi-
cation of the effect of CPA on CSC.
CPA treatment caused a 91% loss of CD44+ CD24− lin− cells in
CPA-treated xenografts compared with controls (Figure 2, A and C ).
In controls, 2.5 ± 0.2% of cells were CD44+ CD24− lin−, whereas
xenografts from CPA-treated mice contained 0.24 ± 0.09% CD44+
CD24− lin− cells. Further analysis of ALDH1 activity as a CSC marker
was performed using the ALDEFLUOR Kit. There was a 64%
decrease in BAAA+ cells in CPA-treated xenografts compared with
controls (Figure 2, B and D). ALDH1 activity was detected in 4.7 ±
0.4% of cells from untreated xenografts but in only 1.7 ± 0.4% of cells
from CPA-treated xenografts.
We further investigated ALDH1-expressing cells in xenografts
using immunofluorescence. In controls, ALDH1+ cells were distributed
throughout the xenograft (Figure 2E ). Two weeks after CPA treat-
ment, xenografts showed substantially reduced numbers of ALDH1
immunofluorescent cells, in agreement with the flow cytometry data.
Figure 1. Characterization of tumor response to CPA. Hematoxylin/
eosin staining of a section froma control tumor (A) and a CPA-treated
tumor (B). (C) Progression of tumors treated at days 0 to 6 with
CPA, relative to tumor volume. Control tumors were of similar size
to treated tumors at the initiation of treatment. *P < .05, compared
with day 0, t test, n = 4.
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Thus, CPA treatment of MC1 breast xenografts results in a loss of
cells bearing CSC markers or in a loss in the markers themselves.
This is consistent with the conclusion that MC1 breast CSCs are
sensitive to CPA compared with the non-CSC population. However,
loss of CSC phenotypic markers could also indicate a change in the
expression without alteration of stem cell activity.
CPA-Treated Xenografts Lose Functional CSC Activity
A functional stem cell assay was performed to determine whether
changes in phenotypic markers as measured by flow cytometry and
immunofluorescence represent actual changes in CSC activity. This
was done by harvesting control and CPA-treated xenografts and in-
jecting 105 or 3 × 104 cells into the mammary fat pad of secondary
mice. The time required to produce a tumor was recorded. If abla-
tion of CSC activity occurred after CPA treatment of primary mice,
then the time required to produce a tumor should be delayed, relative
to controls, and the proportion of animals generating tumors should
be reduced. If CPA treatment resulted in the enrichment of CSC,
then the time to tumor formation should be accelerated compared
with controls, and a greater or equal proportion of animals should
produce tumors.
Injection of cells from control tumors produced tumors in second-
ary mice with 100% efficiency (10/10). The median time to tumor
formation was determined to be 31 and 38 days for injection of 105
and 3 × 104 cells, respectively (Figure 3A). In contrast, when cells
from CPA-treated tumors were injected into secondary mice, only
one of six formed a tumor at the 105 cell dose at 56 days, and none
of five formed a tumor at the 3 × 104 dose, when followed for up to
100 days. Thus, CSC activity was reduced in CPA-treated tumors
compared with controls (P < .05), consistent with loss of the marker
phenotype by flow cytometry and immunofluorescence, and sup-
porting the hypothesis that MC1 CSCs are sensitive to CPA.
Discussion
Tumor resistance to therapy has recently been attributed to intrinsic
resistance of CSC [3]. It has been proposed that the reduction in
tumor size during chemotherapy is due to killing of more sensitive
tumor cells without CSC activity, whereas the CSCs are spared and
drive regrowth of the tumor. We therefore tested the hypothesis that
breast CSCs are resistant to CPA and performed in vivo functional
analysis to determine CSC activity. In contrast to a previous report
that beast CSCs are resistant to neoadjuvant therapy with docetaxel
Figure 2. Effect of CPA on CSC markers. (A) Flow cytometric detection of CD44+ CD24− lin− cells in control and treated xenografts.
(B) Flow cytometric detection of ALDH activity in control and treated xenografts. BAAA is the fluorescent product indicating ALDH ac-
tivity. (C) Compiled data of CD44+ CD24− flow cytometry. (D) Compiled data of ALDEFLUOR flow cytometry. *P < .05 compared with
control, t test, n = 6-12. (E) Control and treated tumor sections were stained for ALDH1. Green indicates ALDH1 staining; blue, nuclear
DAPI staining.
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or doxorubicin and CPA [3], we find a case in which breast CSCs are
sensitive to CPA alone. The data show a reduction in the proportion
of cells bearing the breast CSC phenotype using two distinct defini-
tions [4,5]. CD44+ CD24− lin− cells are reduced as well as BAAA+
cells in the ALDEFLUOR enzymatic assay. In addition, ALDH1 im-
munofluorescence of sections from treated tumors show reduced
ALDH1+ cells, in agreement with the ALDEFLUOR assay results.
Importantly, we show reduced functional stem cell activity in CPA-
treated xenografts.
A functional assay is important for stem cell studies because pheno-
typic markers define a population that is enriched for stem cells but
that also contains non–stem cells. This was demonstrated by the study
of Ginestier et al. [5], in which the overlap of breast tumor CD44+
CD24− cells and BAAA+ cells (containing ALDH activity) was found
to be more enriched for functional stem cell activity than either popula-
tion alone. In addition, the BAAA− component of CD44+ CD24− cells
had little to no functional stem cell activity. Hence, a simple analysis of
marker-positive populations by flow cytometry is not sufficiently ro-
bust to prove that an intervention affected CSC.
One weakness of the current study is that it is limited to one tu-
mor type. However, it adequately proves the hypothesis that all breast
CSCs are resistant to therapy is false. Given the cases of glioblas-
toma displaying sensitivity to specific therapies [6,7], it is likely that
more CSCs will be found to be sensitive. Li et al. [3] showed that
breast CSCs have the general property of chemotherapy resistance at
the population level, but it is not known if some patient tumors in
their sample behaved like this one but are obscured by most resistant
CSC samples.
The mechanism responsible for CSC sensitivity in this sample is
currently an area of investigation. ALDH expression can detoxify
CPA active metabolites and has been thought to mediate stem cell
resistance to this agent [8]. Whereas theoretically true, much direct
data demonstrating this are in the context of ALDH gene transfer,
leading to overexpression [9,10]. Endogenous levels of ALDH may
not be sufficient to confer resistance at the cellular level, as has been
demonstrated by Levi et al. [11]. In hepatocellular CSCs, CPA treat-
ment resulted in the enrichment of CSCs [12]. The liver is a major
site for CPA detoxification, which may explain this observation [11].
In our study, endogenous levels of ALDH do not seem to be suffi-
cient to confer CPA resistance in CSCs at the clinically relevant dose
given. Therefore, other mechanisms must be responsible for confer-
ring sensitivity, possibly related to the DNA damage response associ-
ated with CPA.
The hypothesis that all CSCs are resistant to chemotherapy may
be an oversimplification that fails to take into account potentially im-
portant genetic and epigenetic differences between human patients,
which may contribute to individual tumor response. We demonstrate
here a case in which a patient-derived tumor exhibits sensitivity to
CPA. Thus, the assumption that breast CSCs are globally resistant
to CPA is false, and further investigation of the extent and frequency
of this phenomenon is an important extension of this work. It will be
important to take individual responses into account when designing
clinical trials targeting CSCs, just as with any other targeted therapy.
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Figure 3. Functional assay for CSC activity. Cells from control and
CPA-treated tumors were injected into the mammary fat pad of
mice at the indicated cell quantities, and the number of days re-
quired for tumor formation was recorded. No tumors formed after
injection of 3 × 104 cells from CPA-treated tumors after 100 days
of observation.
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